Latest & greatest articles for colorectal cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on colorectal cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on colorectal cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for colorectal cancer

81. Exploration of time points and cut-off values for early tumour shrinkage to predict survival outcomes of patients with metastatic colorectal cancer treated with first-line chemotherapy using a biexponential model for change in tumour size

Exploration of time points and cut-off values for early tumour shrinkage to predict survival outcomes of patients with metastatic colorectal cancer treated with first-line chemotherapy using a biexponential model for change in tumour size 1 Sakamaki K, et al. ESMO Open 2017;2:e000275. doi:10.1136/esmoopen-2017-000275 Open Access AbstrAct Background Several studies reported that early tumour shrinkage (ETS) was associated with overall survival in patients with metastatic colorectal cancer (mCRC (...) with the actual measured sizes well. Multivariate Cox regression analysis, including performance status, number of metastatic sites and use of targeted agents, showed that ETS at 8 weeks based on a cut-off value of 20% was most significantly associated with overall survival (HR: 0.404, 95% CI 0.231 to 0.707, P=0.0015). Conclusion It is suggested that a time point of 8 weeks and a cut-off value of 20% may be optimal criteria for defining ETS. IntRoduCtIon Colorectal cancer (CRC) is the third and the second

ESMO open2017 Full Text: Link to full Text with Trip Pro

83. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials

First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials 28781171 2017 08 07 2017 09 25 2017 09 25 1474-5488 18 9 2017 Sep The Lancet. Oncology Lancet Oncol. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (...) (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. 1159-1171 S1470-2045(17)30457-6 10.1016/S1470-2045(17)30457-6 Data suggest selective internal radiotherapy (SIRT) in third-line or subsequent therapy for metastatic colorectal cancer has clinical benefit in patients with colorectal liver metastases with liver-dominant disease after chemotherapy. The FOXFIRE, SIRFLOX, and FOXFIRE-Global randomised studies evaluated the efficacy of combining

EvidenceUpdates2017 Full Text: Link to full Text with Trip Pro

84. Human microbiome signatures of differential colorectal cancer drug metabolism

Human microbiome signatures of differential colorectal cancer drug metabolism 29104759 2018 11 13 2055-5008 3 2017 NPJ biofilms and microbiomes NPJ Biofilms Microbiomes Human microbiome signatures of differential colorectal cancer drug metabolism. 27 10.1038/s41522-017-0034-1 It is well appreciated that microbial metabolism of drugs can influence treatment efficacy. Microbial β-glucuronidases in the gut can reactivate the excreted, inactive metabolite of irinotecan, a first-line (...) chemotherapeutic for metastatic colorectal cancer. Reactivation causes adverse drug responses, including severe diarrhea. However, a direct connection between irinotecan metabolism and the composition of an individual's gut microbiota has not previously been made. Here, we report quantitative evidence of inter-individual variability in microbiome metabolism of the inactive metabolite of irinotecan to its active form. We identify a high turnover microbiota metabotype with potentially elevated risk

NPJ biofilms and microbiomes2017 Full Text: Link to full Text with Trip Pro

85. Colorectal Cancer Screening: What Is the Population's Opinion

Colorectal Cancer Screening: What Is the Population's Opinion 29662929 2018 11 14 2341-4545 25 2 2018 Mar GE Portuguese journal of gastroenterology GE Port J Gastroenterol Colorectal Cancer Screening: What Is the Population's Opinion. 62-67 10.1159/000480705 Colorectal cancer (CRC) is the first cause of death by cancer in Portugal and mortality has been increasing in the last 30 years. During a raising awareness campaign performed by our Gastroenterology Department, in Setúbal, Portugal (...) , an anonymous written questionnaire was developed and presented in order to evaluate the population's knowledge and attitude regarding CRC screening. The following results were reported: 140 persons; mean age 54.6 years; 61.4% women; 22.1% had a family history of colorectal cancer. The main risk factors mentioned by the respondents were family history of CRC, previous history of intestinal polyps, and intestinal infection. Screening was considered useful by all respondents. About 60% of the respondents had

GE Portuguese journal of gastroenterology2017 Full Text: Link to full Text with Trip Pro

86. P-Cadherin (CDH3) is overexpressed in colorectal tumors and has potential as a serum marker for colorectal cancer monitoring

P-Cadherin (CDH3) is overexpressed in colorectal tumors and has potential as a serum marker for colorectal cancer monitoring 29142905 2018 11 13 2331-4737 4 9-10 2017 Sep Oncoscience Oncoscience P-Cadherin (CDH3) is overexpressed in colorectal tumors and has potential as a serum marker for colorectal cancer monitoring. 139-147 10.18632/oncoscience.370 Placental-Cadherin (CDH3) is a cell adhesion molecule vital to cellular localization and tissue integrity. It is highly expressed in the placenta (...) (PLC)and is overexpressed by many types of cancer. P-cadherin levels in colorectal cancer (CRC) remains poorly characterized. This study's purpose was to determine P-cadherin expression in CRC and normal tissues and to assess plasma CDH3 levels in order to determine the relationship, if any, between cancer stage, P-cadherin expression and plasma CDH3 levels. An IRB approved plasma, tumor, and prospective data bank was utilized. CRC patients for whom tumor and normal colon tissue samples were

Oncoscience2017 Full Text: Link to full Text with Trip Pro

87. Screening for Colorectal Cancer With Fecal Immunochemical Testing With and Without Postpolypectomy Surveillance Colonoscopy: A Cost-Effectiveness Analysis.

Screening for Colorectal Cancer With Fecal Immunochemical Testing With and Without Postpolypectomy Surveillance Colonoscopy: A Cost-Effectiveness Analysis. Background: Population-based screening to prevent colorectal cancer (CRC) death is effective, but the effectiveness of postpolypectomy surveillance is unclear. Objective: To evaluate the additional benefit in terms of cost-effectiveness of colonoscopy surveillance in a screening setting. Design: Microsimulation using the ASCCA (Adenoma (...) and Serrated pathway to Colorectal CAncer) model. Data Sources: Dutch CRC screening program and published literature. Target Population: Asymptomatic persons aged 55 to 75 years without a prior CRC diagnosis. Time Horizon: Lifetime. Perspective: Health care payer. Intervention: Fecal immunochemical test (FIT) screening with colonoscopy surveillance performed according to the Dutch guideline was simulated. The comparator was no screening or surveillance. FIT screening without colonoscopy surveillance

Annals of Internal Medicine2017

88. Molecular testing for Lynch syndrome in people with colorectal cancer: systematic reviews and economic evaluation

Molecular testing for Lynch syndrome in people with colorectal cancer: systematic reviews and economic evaluation Molecular testing for Lynch syndrome in people with colorectal cancer: systematic reviews and economic evaluation Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find (...) the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> {{metadata.Title}} {{metadata.Headline}} Microsatellite instability and immunohistochemistry will identify most cases of Lynch syndrome in colorectal cancer but there is no high-quality evidence that screening improves long-term outcomes {{author}} {{($index , , , , , & . Tristan Snowsill 1, * , Helen Coelho 1 , Nicola Huxley 1 , Tracey Jones-Hughes 1 , Simon Briscoe 1 , Ian M Frayling 2 , Chris Hyde 1 1 Peninsula Technology

NIHR HTA programme2017

89. Patient navigation to reduce social inequalities in colorectal cancer screening participation: A cluster randomized controlled trial

Patient navigation to reduce social inequalities in colorectal cancer screening participation: A cluster randomized controlled trial 28823681 2017 08 21 2017 09 09 1096-0260 103 2017 Oct Preventive medicine Prev Med Patient navigation to reduce social inequalities in colorectal cancer screening participation: A cluster randomized controlled trial. 76-83 S0091-7435(17)30297-9 10.1016/j.ypmed.2017.08.012 Despite free colorectal cancer screening in France, participation remains low and low (...) socioeconomic status is associated with a low participation. Our aim was to assess the effect of a screening navigation program on participation and the reduction in social inequalities in a national-level organized mass screening program for colorectal cancer by fecal-occult blood test (FOBT). A multicenter (3 French departments) cluster randomized controlled trial was conducted over two years. The cluster was a small geographical unit stratified according to a deprivation index and the place of residence

EvidenceUpdates2017

90. The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and economi

The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and economi The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review (...) and economic evaluation The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and economic evaluation Huxley N, Crathorne L, Varley-Campbell J, Tikhonova I, Snowsill T, Briscoe S, Peters J, Bond M, Napier M & Hoyle M. Record Status This is a bibliographic record of a published health technology assessment from a member

Health Technology Assessment (HTA) Database.2017

91. Molecular testing for Lynch syndrome in people with colorectal cancer: systematic reviews and economic evaluation

Molecular testing for Lynch syndrome in people with colorectal cancer: systematic reviews and economic evaluation Molecular testing for Lynch syndrome in people with colorectal cancer: systematic reviews and economic evaluation Molecular testing for Lynch syndrome in people with colorectal cancer: systematic reviews and economic evaluation Snowsill T, Coelho H, Huxley N, Jones-Hughes T, Briscoe S, Frayling I M & Hyde C. Record Status This is a bibliographic record of a published health (...) technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Snowsill T, Coelho H, Huxley N, Jones-Hughes T, Briscoe S, Frayling I M & Hyde C.. Molecular testing for Lynch syndrome in people with colorectal cancer: systematic reviews and economic evaluation. Health Technology Assessment 2017; 21(51) Authors' objectives Inherited mutations in deoxyribonucleic acid (DNA) mismatch repair (MMR) genes lead to an increased risk

Health Technology Assessment (HTA) Database.2017

92. Hepatic Metastasis from Colorectal Cancer

Hepatic Metastasis from Colorectal Cancer 29201802 2018 11 13 2231-5047 7 2 2017 Jul-Dec Euroasian journal of hepato-gastroenterology Euroasian J Hepatogastroenterol Hepatic Metastasis from Colorectal Cancer. 166-175 10.5005/jp-journals-10018-1241 The liver is the most common site of metastasis in patients with colorectal cancer due to its anatomical situation regarding its portal circulation. About 14 to 18% of patients with colorectal cancer present metastasis at the first medical (...) consultation, and 10 to 25% at the time of the resection of the primary colorectal cancer. The incidence is higher (35%) when a computed tomography (CT) scan is used. In the last decades, a significant increase in the life expectancy of patients with colorectal cancer has been achieved with different diagnostic and treatment programs. Despite these improvements, the presence of metastasis, disease recurrence, and advanced local tumors continue to remain poor prognostic factors. Median survival without

Euroasian journal of hepato-gastroenterology2017 Full Text: Link to full Text with Trip Pro

93. Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme

Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme 29018575 2018 11 13 2059-7029 2 4 2017 ESMO open ESMO Open Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme. e000229 10.1136/esmoopen-2017-000229 TAS-102 improves overall survival (...) (OS) in patients with metastatic colorectal cancer (mCRC) refractory to standard treatments. However, predictive biomarkers of efficacy are currently lacking. We treated a cohort of 43 chemorefractory mCRC patients treated with TAS-102, in a single institution expanded access, compassionate use programme. We stratified patients in two groups according to number of cycles received (<6 cycles and ≥6 cycles). OS, progression-free survival (PFS) and safety were evaluated. Thirteen out of 43 patients

ESMO open2017 Full Text: Link to full Text with Trip Pro

94. Effect of Physician Notification Regarding Nonadherence to Colorectal Cancer Screening on Patient Participation in Fecal Immunochemical Test Cancer Screening: A Randomized Clinical Trial.

Effect of Physician Notification Regarding Nonadherence to Colorectal Cancer Screening on Patient Participation in Fecal Immunochemical Test Cancer Screening: A Randomized Clinical Trial. Importance: Increasing participation in fecal screening tests is a major challenge in countries that have implemented colorectal cancer (CRC) screening programs. Objective: To determine whether providing general practitioners (GPs) a list of patients who are nonadherent to CRC screening enhances patient

JAMA2017 Full Text: Link to full Text with Trip Pro

95. Effect of Colonoscopy Outreach vs Fecal Immunochemical Test Outreach on Colorectal Cancer Screening Completion: A Randomized Clinical Trial.

Effect of Colonoscopy Outreach vs Fecal Immunochemical Test Outreach on Colorectal Cancer Screening Completion: A Randomized Clinical Trial. Importance: Mailed fecal immunochemical test (FIT) outreach is more effective than colonoscopy outreach for increasing 1-time colorectal cancer (CRC) screening, but long-term effectiveness may need repeat testing and timely follow-up for abnormal results. Objective: Compare the effectiveness of FIT outreach and colonoscopy outreach to increase completion (...) was detected. Secondary outcomes included detection of any adenoma or advanced neoplasia (including CRC) and screening-related harms (including bleeding or perforation). Results: All 5999 participants (median age, 56 years; women, 61.9%) were included in the intention-to-screen analyses. Screening process completion was 38.4% in the colonoscopy outreach group, 28.0% in the FIT outreach group, and 10.7% in the usual care group. Compared with the usual care group, between-group differences for completion

JAMA2017 Full Text: Link to full Text with Trip Pro

96. Erratum: Clinical responses to ERK inhibition in BRAFV600E-mutant colorectal cancer predicted using a computational model

Erratum: Clinical responses to ERK inhibition in BRAFV600E-mutant colorectal cancer predicted using a computational model 28879057 2017 09 07 2056-7189 3 2017 NPJ systems biology and applications NPJ Syst Biol Appl Erratum: Clinical responses to ERK inhibition in BRAF V600E -mutant colorectal cancer predicted using a computational model. 25 10.1038/s41540-017-0026-z [This corrects the article DOI: 10.1038/s41540-017-0016-1.]. Kirouac Daniel C DC Genentech Research & Early Development, 1 DNA Way

NPJ systems biology and applications2017 Full Text: Link to full Text with Trip Pro

97. Effect of Adjuvant Chemotherapy on Elderly Colorectal Cancer Patients: Lack of Evidence

Effect of Adjuvant Chemotherapy on Elderly Colorectal Cancer Patients: Lack of Evidence 29071260 2018 11 13 2296-3774 4 1-2 2017 Sep Gastrointestinal tumors Gastrointest Tumors Effect of Adjuvant Chemotherapy on Elderly Colorectal Cancer Patients: Lack of Evidence. 11-19 10.1159/000479318 Adjuvant chemotherapy has become the standard form of treatment for all patients with stage III colorectal cancer and is also recommended for patients with stage II disease and defined risk factors. However (...) , clinical studies that evaluate the effect of adjuvant treatment regimens have a selection bias in favor of younger patients, so that even retrospective subgroup analyses cannot define the best therapeutic procedure in elderly patients with comorbidities. As long as the role of adjuvant chemotherapy in elderly colorectal cancer patients is not investigated in comprehensive trials, no clear recommendations are possible. An exploratory review of the relevant literature revealed that a formal meta-analysis

Gastrointestinal tumors2017 Full Text: Link to full Text with Trip Pro

98. Nivolumab (Opdivo) + Ipilimumab (Yervoy) for metastatic colorectal cancer patients with deficient DNA mismatch repair mechanism (dMMR) or high microsatellite instability (MSI-H)

Nivolumab (Opdivo) + Ipilimumab (Yervoy) for metastatic colorectal cancer patients with deficient DNA mismatch repair mechanism (dMMR) or high microsatellite instability (MSI-H) Nivolumab (Opdivo) + Ipilimumab (Yervoy) for metastatic colorectal cancer patients with deficient DNA mismatch repair mechanism (dMMR) or high microsatellite instability (MSI-H) ‐ NIHR Innovation Observatory ☰ Menu Search Filter by Specialty Filter by Year Nivolumab (Opdivo) + Ipilimumab (Yervoy) for metastatic (...) colorectal cancer patients with deficient DNA mismatch repair mechanism (dMMR) or high microsatellite instability (MSI-H) August 2017 Technology Description: Nivolumab and ipilimumab is a combination therapy to treat cancer of the large bowel (colon) or back passage (rectum) – these types of cancers (bowel and colon) are also known as colorectal cancer. Metastatic colorectal cancer occurs when the cancer has spread to another part of the body; this is most commonly to the liver. A small proportion

NIHR Innovation Observatory2017

99. Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study

Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study 29209533 2018 11 13 2059-7029 2 3 2017 ESMO open ESMO Open Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study. e000241 10.1136/esmoopen-2017-000241 BRAF V600E mutation defines a specific colorectal cancer (CRC) subgroup with poor prognosis. Promising preclinical data showed synthetically lethal activity of mitotic (...) and Experimental Oncology, Istituto Oncologico Veneto IRCCS, Padua, Italy. Lonardi Sara S Unit of Medical Oncology 1, Department of Clinical and Experimental Oncology, Istituto Oncologico Veneto IRCCS, Padua, Italy. eng Journal Article 2017 08 10 England ESMO Open 101690685 2059-7029 BRAFV600E Vinorelbine metastatic colorectal cancer Competing interests: None declared. 2017 06 29 2017 07 14 2017 07 17 2017 12 7 6 0 2017 12 7 6 0 2017 12 7 6 1 epublish 29209533 10.1136/esmoopen-2017-000241 esmoopen-2017-000241

ESMO open2017 Full Text: Link to full Text with Trip Pro

100. Colorectal Cancer Mortality Rates in Adults Aged 20 to 54 Years in the United States, 1970-2014

Colorectal Cancer Mortality Rates in Adults Aged 20 to 54 Years in the United States, 1970-2014 28787497 2017 09 20 2018 11 13 1538-3598 318 6 2017 08 08 JAMA JAMA Colorectal Cancer Mortality Rates in Adults Aged 20 to 54 Years in the United States, 1970-2014. 572-574 10.1001/jama.2017.7630 Siegel Rebecca L RL Surveillance and Health Services Research Program, American Cancer Society, Atlanta, Georgia. Miller Kimberly D KD Surveillance and Health Services Research Program, American Cancer (...) Society, Atlanta, Georgia. Jemal Ahmedin A Surveillance and Health Services Research Program, American Cancer Society, Atlanta, Georgia. eng Letter United States JAMA 7501160 0098-7484 AIM IM Adult African Americans Age Distribution Colorectal Neoplasms ethnology mortality European Continental Ancestry Group Female Humans Male Middle Aged Mortality trends United States epidemiology Young Adult 2017 8 9 6 0 2017 8 9 6 0 2017 9 21 6 0 ppublish 28787497 2647859 10.1001/jama.2017.7630 PMC5817468 Cancer

JAMA2017 Full Text: Link to full Text with Trip Pro